| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281527 | Clinical Gastroenterology and Hepatology | 2016 | 7 Pages |
Abstract
On the basis of a retrospective study, in patients with IBD and a history of cancer, exposure to an anti-TNF agent or an antimetabolite after cancer was not associated with an increased risk of incident cancer, compared with patients who did not receive immunosuppression. Larger, matched, prospective studies are needed to confirm these findings.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, Stefano Malerba, Ashwin Ananthakrishnan, Vijay Yajnik, Gila Hoffman, Manasi Agrawal, Dana Lukin, Amit Desai, Elisa McEachern, Brian Bosworth, Ellen Scherl, Andre Reyes, Hina Zaidi,